Anti-dsDNA antibody subtypes and anti-C1q antibodies: toward a more reliable diagnosis and monitoring of systemic lupus erythematosus and lupus nephritis

Abstract

The putative distinct diagnostic and pathogenic potential of aDNA-Ab subtypes, differing in their affinity or epitope specificity, was subject of several studies with controversial results. Comparing five assays, characterized by different reaction conditions and nature/source of dsDNA, we investigated the abovementioned problem in a retrospective study on 100 systemic lupus erythematosus (SLE) patients and 100 controls (other CTD, autoimmune hepatopathies). As demonstrated, only assay 3 (Farrzyme, TBS, UK) and 5 (Farr-RIA, Trinity Biotech, Ireland) are really suitable to detect primarily high avidity aDNA-Ab. Both were significantly linked to lupus nephritis (specificity 84%) and highly specific for SLE (95 and 96%). Thereby, assay 3 was found to be the first solid phase ELISA probably suitable to replace the Farr-RIA. Classical ELISAs (assay 1, Orgentec, Germany, and 2, Bindazyme, TBS, UK), detecting aDNA-Ab more or less independent from their avidity, or tests with only intermediate specificity for high avidity Ab (assay 4, ELIAdn, Sweden Diagnostics, Germany), were less specific for SLE (83, 79, 91%, respectively) and not associated with renal involvement (specificity 54-57%). At least in the patients studied here, obvious antigen-related differences could not be observed. With slight differences, all assays were suitable to monitor disease activity and therapy in SLE, agreeing with the ECLAM score in about 70-80% of cases. For lupus nephritis, aC1q-Ab are as specific as high avidity aDNA-Ab and capable to close a diagnostic gap in some cases. Thus, to enhance the specificity (up to 98%) and to consider the distinct diagnostic/pathogenic potential of aDNA-Ab subtypes in SLE, under routine clinical laboratory conditions it should be recommended to combine a sensitive screening test with a more specific second assay.

Keywords

aC1q-Ab aDNA-Ab diagnostic/pathogenic potential lupus nephritis SLE

Get full access to this article

View all access options for this article.

References

Uwatoko S , Mannik M. Low molecular weight C1q-binding immunoglobulin G in patients with systemic lupus erythematosus consists of autoantibodies to the collagen-like region of C1q . J Clin Invest 1988; 82: 816-824 .

Tan EM , Cohen AS , Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1982; 25: 271-277 .

Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1997; 40: 1725-1725 .

Vitali C , Bencivelli W , Isenberg DA et al. Disease activity in SLE: report of the Consensus study group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease activity in SLE . Clin Exp Rheumatol 1992; 10: 541-547 .

Rahman A , Hiepe F. Anti-DNA antibodies: overview of assays and clinical correlations . Lupus 2002; 11: 770-773 .

Isenberg D , Smeenk R.

Clinical laboratory assays for measuring anti-dsDNA antibodies. Where are we now?

Lupus 2002; 11: 797-800 .

Schiffer LE , Hussain N , Wang X et al.

Lowering anti-dsDNA antibodies: what’s new?

Lupus 2002; 11: 885-894 .

Rekvig OP , Nossent JC. Anti-double-stranded DNA antibodies, nucleosomes, and systemic lupus erythematosus . Arthritis Rheum 2003; 48: 300-312 .

Isenberg D.

Anti-dsDNA antibodies: still a useful criterion for patients with systemic lupus erythematosus?

Lupus 2004; 13: 881-885 .

10.

Haugbro K , Nossent JC , Winkler T , Figenschau Y , Rekvig OP. Anti-dsDNA antibodies and disease classification in antinuclear antibody positive patients: the role of analytical diversity . Ann Rheum Dis 2004; 63: 386-394 .

11.

Reichlin M , Wolfson-Reichlin M. Correlations of anti-dsDNA and anti-ribosomal P autoantibodies with lupus nephritis . Clin Immunol 2003; 108: 69-72 .

12.

Nossent HC , Rekvig OP.

Is closer linkage between systemic lupus erythematosus and anti-double-stranded DNA antibodies a desirable and attainable goal?

Arthritis Res Ther 2005; 7: 85-87 .

13.

Riemekasten G , Marell J , Trebeljahr G et al. A novel epitope on the C-terminus of SmD1 is recognized by the majority of sera from patients with systemic lupus erythematosus . J Clin Invest 1998; 102: 754-763 .

14.

Jaekel H-P , Klopsch T , Benkenstein B et al. Reactivities to the Sm autoantigenic complex and the synthetic SmD1-aa83-119 peptide in systemic lupus erythematosus and other autoimmune diseases . J Autoimmunity 2001; 17: 347-354 .

15.

Uwatoko S , Aoutsuka S , Osawa M et al. Characterization of C1q-binding IgG complexes in systemic lupus erythematosus . Clin Immunol Immunopathol 1984; 30: 104-116 .

16.

Conrad K , Schoessler W , Hiepe F , with contributions of Fritzler M. Autoantibodies in systemic autoimmune diseases. A diagnostic reference. Pabst Science Publishers , 2002: 46-47.

17.

Rekvig OP , Kalaaji M , Nossent HC. Anti-DNA antibody subpopulations and lupus nephritis . Autoimmunity Reviews 2004; 3: 91-96 .

18.

Werle E , Blazek M , Fiehn W. The clinical significance of measuring different anti-dsDNA antibodies by using the Farr assay, an enzyme immunoassay and a Crithidia luciliae immunofluorescence test . Lupus 1992; 1: 369-377 .

19.

Linnemann M , Geisen C , Menn S , Herzberg C , Dinser R , Wielckens K. Comparison of three dsDNA-ELISAs with regard to their efficiency in the diagnosis of systemic lupus erythematosus . Clin Lab 2002; 48: 45-52 .

20.

Hernando M , Gonzalez C , Sanchez A et al. Clinical evaluation of a new automated anti-dsDNA fluorescent immunoassay . Clin Chem Lab Med 2002; 40: 1056-1060 .

21.

Villalta D , Bizzaro N , Corazza D , Tozzoli R , Tonutti E. Evaluation of a new automated enzyme fluoroimmunoassay using recombinant plasmid dsDNA for the detection of anti-dsDNA antibodies in SLE . J Clin Lab Anal 2002; 16: 227-232 .

22.

Derksen RHWM , Bast EJEG , Strooisma T , Jacobs JWG. A comparison between the Farr radioimmunoassay and a new automated fluorescence immunoassay for the detection of antibodies against double stranded DNA in serum . Ann Rheum Dis 2002; 61: 1099-1102 .

23.

Chen C-Y , Tseng H-M , Chen L-C et al. Use of a new fluorescence immunoassay to detect anti-dsDNA antibodies is more correlated with disease activity and complement than the ELISA method in SLE patients . Lupus 2003; 12: 266-273 .

24.

Villalta D , Romelli PB , Savina C et al. Anti-dsDNA antibody avidity determination by a simple reliable ELISA method for SLE diagnosis and monitoring . Lupus 2003; 12: 31-36 .

25.

Riboldi P , Gerosa M , Moroni G et al.

Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus?

Autoimmunity 2005; 38: 39-45 .

26.

Budd R , Taylor D , Harley E , Isenberg DA , Bradwell AR. Comparison of two Farr RIA methods and an ELISA assay for the detection of high avidity anti-dsDNA antibodies . Clin Chem 2005; 51 (Suppl. B-80): pA75-pA75 (abstract).

27.

Okamura M , Kanagama Y , Amastu K et al. Significance of ELISA for antibodies to dsDNA in patients with lupus nephritis: correlation with severity of renal histology . Ann Rheum Dis 1993; 52: 14-20 .

28.

Witte T , Hartung K , Sachse C et al. IgM-antiDNA antibodies in systemic lupus erythematosus: negative association with nephritis . Rheumatol Int 1998; 18: 85-91 .

29.

Foerger F , Matthias T , Oppermann M , Becker H , Helmke K. Clinical significance of anti-dsDNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a prognostic marker for lupus nephritis . Lupus 2004; 13: 36-44 .

30.

Bizzaro N , Villalta D , Tonutti E et al. The diagnostic and prognostic role of anti-C1q antibodies in systemic lupus erythematosus. In Conrad K , Bachmann MP , Chan EKL , Fritzler MJ , Humbel RL , Sack U , Shoenfeld Y eds. From animal models to human genetics: Research on the induction and pathogenicity of autoantibodies. Pabst Science Publishers , 2004: 347-349.

31.

Miehle N , Petschner F , Nettenbusch B et al. Anti-C1q antibodies in lupus nephritis. In Conrad K , Bachmann MP , Chan EKL , Fritzler MJ , Humbel RL , Sack U , Shoenfeld Y eds. From animal models to human genetics: Research on the induction and pathogenicity of autoantibodies. Pabst Science Publishers , 2004: 350-350 (abstract).

32.

Nossent HC , Henzen-Logmans SC , Vroom TM , Berden JH , Swaak TJ. Contribution of renal biopsy data in predicting outcome of lupus nephritis: analysis of 116 patients . Arthritis Rheum 1990; 33: 970-977 .

33.

Mannik M , Werner MH. Deposition of antibodies to the collagen-like region of C1q in renal glomeruli of patients with proliferative lupus glomerulonephritis . Arthritis Rheum 1997; 40: 1504-1511 .

34.

Crowson AN , Magro C. The cutaneous pathology of lupus erythematosus: a review . J Cutan Pathol 2001; 28: 1-23 .

35.

DeGiorgio LA , Konstantinov KN , Lee SC , Hardin JA , Volpe BT , Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NRS glutamate receptor in systemic lupus erythematosus . Nat Med 2001; 7: 1189-1193 .

36.

Mason LJ , Ravirajan CT , Rahman A , Putterman C , Isenberg DA.

Is alpha-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis?

Arthritis Rheum 2004; 50: 866-870 .

37.

Zhao C , Weinstein E , Tuzowa M et al. Cross-reactivity of human lupus anti-DNA antibodies with alpha-actinin and nephritogenic potential . Arthritis Rheum 2005; 52: 522-530 .

38.

Swaak AJG , Aarden LA , Statius van Eps LW , Felthamp TEW. Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus . Arthritis Rheum 1979; 22: 236-245 .

39.

Isenberg DA , Garton M , Reichlin MW , Reichlin M. Long term follow up of autoantibody profiles in black female lupus patients and clinical comparison with Caucasian and Asian patients . Br J Rheum 1997; 36: 229-233 .